Amid complaints from shareholder activists, Endo International (ENDP) has issued a report about the risks of selling opioid painkillers and agreed to expand a so-called clawback policy for executive compensation when negligence occurs. The company will also beef up disclosure of its lobbying efforts.

The move is the latest victory for Investors for Opioid Accountability, a coalition of institutional investors that has been pushing drug makers, wholesalers, and pharmacies to take steps to rein in the opioid crisis by changing business practices. Previously, Assertio Therapeutics (ASRT) agreed to monitor opioid risks, but Endo is the first large drug maker to take a more comprehensive step.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy